Physician
Psychiatry
Dr. Saad A. Shakir, MD
|
|
Give Review
Doctor Saad A. Shakir, MD works in the field of Psychiatry. He attended University of Baghdad College of Medicine. He received awards:"Regional Top Doctor". Saad Shakir is a published doctor. He published 101 publications, including: 'Group therapy in the management of manic-depressive illness.' Saad A. Shakir accepts Medicare payments and is listed with Medicare.gov.
Publications
- Surface smoothing effects of thin film deposition?
- Approximate theory of Stokes amplification and conversion valid at large gain.
- Coupled-mode equations for two weakly guiding single-mode fibers.
- Stevens-Johnson syndrome and antiepileptics.
- Evaluation of patient reporting of adverse drug reactions to the UK ''Yellow Card Scheme'': literature review, descriptive and qualitative analyses, and questionnaire ...
- Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies.
- Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice.
- Finasteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription-event monitoring data.
- The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
- Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study.
- Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality.
- Analysis of grating-coupled surface-emitting lasers.
- Semiclassical theory of coupled lasers.
- Fourier series approach to synthesis.
- Recursive numerical solution for nonlinear wave propagation in fibers and cylindrically symmetric systems.
- Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.
- The negative effect of red tape on research.
- Safety profile of orlistat: results of a prescription-event monitoring study.
- Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
- Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999.
- Observational cohort study to monitor the use and safety of carvedilol in the treatment of heart failure in clinical practice in England--1st interim report.
- Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research ...
- Montelukast and improvement of eczema: observations from a prescription event monitoring study in England.
- The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England.
- Prescription-event monitoring and reporting of adverse drug reactions.
- Monitoring the safety of over the counter drugs. We need a better way than spontaneous reports.
- Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997.
- Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring.
- Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperid...
- Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitori...
- Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England.
- Incompleteness of lamotrigine data.
- Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting.
- Adverse effects associated with the use of donepezil in general practice in England.
- QT lengthening and life-threatening arrhythmias associated with fexofenadine.
- Group therapy in the management of manic-Depressive illness.
- Group psychotherapy as an adjunct to lithium maintenance.
- Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England.
- Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using pre...
- Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using pre...
- Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-e...
- A post-marketing observational study to assess the safety of mibefradil in the community in England.
- Association between SSRIs and upper gastrointestinal bleeding. SSRIs are no more likely than other drugs to cause such bleeding.
- Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK.
- A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil.
- A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.
- Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England.
- Hospital admissions for ''drug-induced'' Disorders in England: a study using the Hospital Episodes Statistics (HES) database.
- Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study.
- Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study.
- Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes.
- Developing tools for the safety specification in risk management plans: lessons learned from a pilot project.
- Paediatric post-marketing pharmacovigilance: comparison of the adverse event profile of vigabatrin prescribed to children and adults.
- Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study.
- New postgraduate qualifications in pharmacovigilance from the Drug Safety Research Unit in the UK.
- Paediatric postmarketing pharmacovigilance using prescription-event monitoring: comparison of the adverse event profiles of lamotrigine prescribed to children and adul...
- European commission consultation on pharmacovigilance.
- A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes.
- Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management.
- Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data.
- Risk of Depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England.
- Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.
- Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management.
- Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
- Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study.
- Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
- Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study.
- Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England.
- Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study.
- The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients.
- Prescriber adoption of newly approved selective COX-2 inhibitors.
- Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.
- Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.
- Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy disp...
- The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
- Under-reporting of adverse drug reactions : a systematic review.
- A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.
- The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.
- Thoughts on signal detection in pharmacovigilance.
- A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance plann...
- Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
- Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance.
- An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease.
- Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.
- Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England.
- Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
- Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction.
- An analysis of the exclusion criteria used in observational pharmacoepidemiological studies.
- The safety and effectiveness of newer antiepileptics: a comparative postmarketing cohort study.
- Bill Inman: drug safety physician and pharmacoepidemiologist.
- An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.
- Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.
- Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapi...
- Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
- A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
- Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin.
- Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.
- Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
- Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology.
- Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.
Schools
University Of Baghdad College Of Medicine
University Baghdad City Hospital
Ny State Psy Institute
Stanford Hospital
Procedures Preformed
- Medication Management
Conditions Treated
- Anxiety
- Bipolar Disorder
- Depression
- Major Depressive Disorder
- View All
Doctors Specialties
- Psychiatry
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Stanford University -
University of Baghdad College of Medicine
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1245367374 | |
| NPPES Provider LastName | SHAKIR | |
| NPPES Provider FirstName | SAAD | |
| NPPES Provider ZIPCode | 950322005 | |
| NPPES Provider State | CA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 1778.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1245367374 |
| Last Name Of The Provider | SHAKIR |
| First Name Of The Provider | SAAD |
| View All |
Similar Doctors
|
|
Dr. Perry Segal, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Justine S. Forbes, MD |
|
|
Dr. Susan B. Greenberg-Englander, MD |
|
|
Dr. Sharon L. Paley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria T. Torry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anita Hirsch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marvin S. Rubinstein, MD |